- Veracyte, Inc. (VCYT, Financial) to present 18 abstracts on Decipher Prostate and Bladder Genomic Classifiers at AUA 2025 in Las Vegas.
- Decipher GRID technology fuels new insights into prostate and bladder cancer treatment and molecular characterization.
- Key studies include immune infiltration signatures and regional heterogeneity in prostate cancer.
Veracyte, Inc. (VCYT), a prominent cancer diagnostics company, is set to showcase 18 abstracts at AUA 2025, the annual meeting of the American Urological Association scheduled from April 26-29 in Las Vegas. These presentations will highlight the capabilities of the company's Decipher Prostate and Decipher Bladder Genomic Classifiers, emphasizing new insights into prostate and bladder cancers garnered through the Decipher GRID (Genomic Resource for Intelligent Discovery) research tool.
The studies will delve into various aspects of cancer diagnostics and treatment, including using whole-transcriptome analysis to enhance understanding of tumor biology. One key study by Dr. Vignesh Packiam from Rutgers Cancer Institute will explore the differential therapy responses in high-risk non-muscle-invasive bladder cancer patients, utilizing Decipher GRID to study immune microenvironment gene expression signatures.
Another significant examination by Dr. Nicole Handa from Northwestern University will investigate Grade Group 1 prostate cancer, assessing adverse molecular features that could lead to metastasis. This research contributes to a growing dialogue about whether Grade Group 1 should retain its "cancer" designation due to its perceived lower metastatic potential.
The presentation will also feature research on regional transcriptomic differences in prostate cancer patients, led by Dr. Deepak Kapoor from Icahn School of Medicine at Mount Sinai. This project illustrates the potential of Decipher GRID to inform precision medicine across diverse populations, potentially transforming patient care by tailoring treatment to specific genomic signatures.
Through these presentations, Veracyte underscores its commitment to leveraging its comprehensive genomic resources to enhance cancer diagnostics, ultimately aiding physicians in providing more personalized and effective treatment strategies for their patients.
